Printer Friendly

Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians.

Folate, a water soluble B vitamin, plays a key role in one-carbon metabolism. It is an essential cofactor for de novo biosynthesis of purine and thymidine nucleotide (1,2) (Fig.) with special reference to methylation reactions and epigenetic influences (DNA, chromosomes and mutations) (3). Folate deficiency causes anaemia and is considered to be of aetiopathogenetic importance in several cardiovascular diseases, neural tube defects and other congenital defects, adverse pregnancy outcomes, neuropsychiatric and cognitive disorders, and cancer (4,5). Folate antagonists like methotrexate (MTX) and 5 fluorouracil target folate metabolism. Folate analogue are also widely used to treat cancer, autoimmune diseases, psoriasis, and infections.

Recently, several studies have described SNPs of the genes involved in folate metabolism (6) and their role in related diseases (7-10). Though inadequate, data also suggest that these SNPs may influence therapeutic outcome by playing a critical role in the metabolism of drugs targeting folate biosynthetic pathway (6,11). Importantly, racial and ethnic differences in the occurrence of SNPs have been proposed (12-14).

[FIGURE OMITTED]

The data on the distribution of SNPs (folate pathway) in the Indian population are sparse. Any study on the frequencies of SNPs in disease must be preceded by their distribution in the healthy population. The present study aims to determine the allelic frequency of SNPs across intracellular folate metabolic pathway in healthy Indian subjects. Allele frequencies were also compared with previously reported frequencies by others to address the racial and inter-ethnic differences.

Material & Methods

Study population: One hundred and forty four unrelated healthy subjects of either sex were enrolled in the study from the outpatient rheumatology referral service of Centre for Rheumatic diseases, Pune (west India) from April 2007- January 2008. There were 70 males and 74 females with mean age (SD) of 23.22 (5.3) years. The study protocol was approved by the Ethics Committee of Centre for Rheumatic Diseases, Pune. Subjects willing to participate provided consent as per the guidelines from the Institutional ethics Committee.

Genotype analysis: Post-consent, peripheral blood sample (4-5 ml) was drawn from each healthy subject, and genomic DNA was extracted using Miller's protocol (15). A total of 12 polymorphisms in 9 genes of MTX metabolism (including transporters) were studied. The genes analyzed were MTHFR: Methylenetetrahydrofoate reductase; TS: Thymidylate synthase; RFC1: Reduce folatecarrier1 ;MS: Methionine synthase; SHMT1: Serine hydroxymethyltransferase1; MDR1: Multidrug resistantprotein1; GGH: [gamma] glutamyl hydrolase; ATIC: Aminoimidazol carboxamide ribonucleotide transformylase; MTRR: Methionine synthase reductase. Genotyping was performed using PCR-RFLP technique for MTHFR A1298C (rs1801131) and C677T (rs1801133), TS 5'UTR repeat and 3'UTR deletion, RFC1G80A (rs1051266), MS A2756G (rs1805087), MDR1C3435T (rs1045642) and C1236T (rs1128503), GGH C401T (rs3758149), MTRR A66G (rs1801394) polymorphisms (oligonucleotides-Integrated Biotechnologies, restriction endonucleases

New England Biolabs) (16-18). Real-time Taqman allelic discrimination assay (Applied Biosystems, CA, USA) was used for genotyping ATIC C347G (rs2372536), SHMT1C1420T (rs17829445) polymorphisms (19). After restriction digestion, digested products were visualized on 2 per cent agarose gel except for 5'UTR repeats of TS which were directly visualized after the PCR. Real-time Taqman allelic discrimination assays were performed according to protocols provided by the manufacturer (Applied Biosystems, CA, USA). Samples containing mutants were reanalyzed to ensure the accuracy of the method. There was 100 per cent reproducibility.

Statistical analysis: Statistical analysis was performed using the Graph Pad Prism statistical software (San Diego CA. USA). Allele frequencies were determined for 12 polymorphisms in nine genes in the folate-MTX metabolic pathway in 144 healthy subjects. The frequency of each allele in the study population is given in the Table I. Differences in allele frequencies between healthy subjects and other ethnic groups were measured by Fisher exact test. P< 0.05 was considered statistically significant. The observed genotype frequencies of polymorphisms studied were compared with expected frequencies according to Hardy-Weinberg equilibrium (HWE) using [chi square] tests.

Results & Discussion

We examined allele frequencies for 12 polymorphisms in folate and MTX metabolism among healthy subjects and compared them with the allele distribution in other ethnic groups (Table I). Allele frequencies obtained for the present study were MTHFR 677T (10%) and 1298 C (30%), TS 3UTR 0bp (46%), MDR1 3435T and 1236T (62%), RFC1 80A (57%), GGH 401T (61%), MS 2756G (34%), ATIC 347G (52%) and SHMT1 1420T (80%). The complete genotype distribution for healthy subjects is represented in Table II. Genotype frequencies for all 12 SNPs were in HWE for healthy subjects.

Healthy subjects from our study were compared with healthy subjects from European, African and Indian population (Table I). MTHFR 677T variant allele frequency in European population (32%, P<0.001) was higher than Indian healthy subjects (10%) while TS 3 UTR 0bp (deletion) polymorphism was lower in European (27%, P<0. 001) than Indian (46%). There was no difference in distribution of MTHFR 1298C, MDR1 1236T and MDR1 3435T variant allele frequencies between Indian and European healthy subjects. The occurrence of MTHFR 677T (4%, P<0.001), MTHFR 1298C (13%, P<0.001), MDR1 3435T (10%, P<0.001) and MDR1 1236T (14%, P<0.001) variant alleles was significantly lower in Africans as against Indian healthy subjects.

Comparison of our healthy subjects with Indian study from north India reveals that there was significant difference in the occurrence of GGH 401T, RFC1 80A and MDR1 1236T variant alleles. The occurrence of GGH 401T (61%) and RFC1 80A (57%) in our healthy subjects was higher than north Indian subjects 25 and 28 per cent (P<0.0001) respectively while MDR1 1236T was higher in north Indians (72%) than our healthy subjects (62%, P<0.05). Thus the current report supports the previous findings that the allele or haplotype frequencies of several important polymorphisms in folate pathway vary with race (12-14).

The allele frequencies of MTHFR 1298C and 677T, TYMS 3' UTR deletion and MDR1 3435T and 1236T in healthy subjects are different in Indian subjects as compared to Europeans and Africans (12). The latter conclusion is limited by the fact that we could only find data on five polymorphisms in reports of European and African healthy population. We have also compared our data with north Indian population (20). There are differences in the occurrence of GGH 401T, RFC1 80A and MDR1 1236T variant alleles within Indian population. This intra-ethnic difference can be because Indian population is a conglomeration of multiple culture and evolutionary histories. The evolutionary antiquity of Indian ethnic groups and subsequent migration from central Asia, west Asia and southern China has resulted in a rich tapestry of socio-cultural, linguistic and biological diversity21.

SNPs have been reported per se to impair folate-mediated one-carbon metabolic pathways and contribute to increased risk of several disorders of folate deficiency (22-24). Folate antagonist MTX is among the best-tolerated disease-modifying antirheumatic drugs (DMARDs) used in the treatment of RA, but is confounded by unpredicted interpatient variability in clinical response and toxicity (6,25). To unravel the probable associations among variations in drug pathway alleles and MTX response in Indian rheumatoid arthritis (RA) patients, it is essential to first explore the relationship between the genes coding for folate metabolic pathway and ethnicity. The results of the current study are a step forward in that direction.

To our knowledge this is the first report on 12 polymorphisms in 9 genes of folate metabolic pathway in Indian population. We have not analyzed polymorphisms in folypolyglutamate synthase (FPGS) and dihydrofolate reductase (DHFR). We report ethnic differences in the SNPs in genes coding folate biosynthetic metabolic intracellular pathway. It may not be appropriate to extrapolate the findings of genetic associations influencing folate antagonist treatment response in subjects belonging to Caucasian and African ethnicity to the Indian population. Thus knowledge of allelic frequency distribution within a population can be useful in optimizing doses for therapeutic efficacy, identifying potential risk groups for adverse drug reactions and explaining therapeutic failures.

Acknowledgment

The first author (YG) thanks Council for Scientific and Industrial Research, New Delhi, India, for senior research fellowship. The authors thank the invaluable assistance from CRD for providing logistic and patient support (Ms Anuradha V and Ms Manjit S), Dr Anjali Radkar for giving statistical inputs and Dr Anand Hardikar for providing Applied Biosystems 7500 real time PCR facility at National Center for Cell Sciences, Pune.

Received July 30, 2009

References

(1.) Shane B. Folate chemistry and metabolism. In: Bailey LB, editor. Folate in health and disease. New York: Marcel Dekker; 1995. p. 1-22.

(2.) Wagner C. Biochemical role of folate in cellular metabolism. In: Bailey LB, editor. Folate in health and disease. New York: Marcel Dekker; 1995. p. 23-42.

(3.) Kim YI. Folate and DNA methylation: A mechanistic link between folate deficiency and colorectal cancer? Cancer EpidemiolBiomarkers Prev 2004; 13 : 511-9.

(4.) Bailey LB, Rampersaud GC, Kauwell GP. Folic acid supplements and fortification affect the risk for neural tube defects, vascular disease and cancer: evolving science. J Nutr 2003; 133 : 1961S-68S.

(5.) Kim YI. Role of folate in colon cancer development and progression. JNutr 2003; 133 : 3731S-39S.

(6.) Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism: a promising direction. Pharmacogenomics 2002; 3 : 299-313.

(7.) Fredriksen A, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat 2007; 28 : 856-65.

(8.) Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC, Giovannucci EL, et al. Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006; 15 : 2408-17.

(9.) Lissowska J, Gaudet MM, Brinton LA, Chanock SJ, Peplonska B, Welch R, et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a population-based case-control study and meta-analyses. Int J Cancer 2007; 120 : 2696-03.

(10.) Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, et al. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to

bladder cancer. Int J Cancer 2007; 120 : 2452-8.

(11.) Carr DF, Whiteley G, Alfirevic A, Pirmohamed M. Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics J2009; 9 : 291-305.

(12.) Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon WD, Eisen S, et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 2004; 5 : 559-69.

(13.) Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, et al. Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006; 65 : 1213-8.

(14.) Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35 : 572-9.

(15.) Miller SA, Dykes DD, Polesky HF.A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16 : 1215.

(16.) Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11 : 593-600.

(17.) Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, et al. Contribution of common polymorphisms in reduced folatecarrier and glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14 : 733-9.

(18.) Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70 : 189-99.

(19.) Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006; 54 : 607-12.

(20.) Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, et al. Interaction of genes from influx-metabolism-efflux pathwayand their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 2008; 18 : 1041-9.

(21.) Indian Genome Variation Consortium. Genetic landscape of the people of India: a canvas for disease gene exploration. J Genet 2008; 87 : 3-20.

(22.) Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004; 62 : S3-12.

(23.) Robien K, Ulrich CM.5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk : A huge minireview. Am J Epidemiol 2003; 157 : 571-82.

(24.) O'leary VB, Pangilinan F, Cox C, Parle-McDermott A, Conley M, Molloy AM, et al. Members of the Birth Defects Research Group. Reduced folate carrier polymorphism and neural tube defects. Mol Genet Metab 2006; 87 : 364-9.

(25.) Ranganathan P, McLeod HL. Methotrexate pharmacogenetics the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54 : 1366-77.

Reprint requests: Dr Arvind Chopra, Director, Centre for Rheumatic Diseases, 11, Hermes Elegance, 1988 Convent Street Camp, Pune 411 001, India e-mail: crdp@vsnl.net

Yogita Ghodke, Arvind Chopra *, Pooja Shintre **, Amrutesh Puranik, Kalpana Joshi ** & Bhushan Patwardhan

Interdisciplinary School of Health Sciences (ISHS), University of Pune, 'Centre for Rheumatic Diseases (CRD) & "Department of biotechnology, Sinhgad College of Engineering, Pune, India
Table I. The allele frequency of SNP across intracellular folate
metabolic pathway in Indian population in the current study and
comparison with others

                Present study      European (14)
               healthy subjects   healthy subjects
Polymorphism        n=144               n=95

MTHFR C677T
C allele             0.90               0.68
T allele             0.10               0.32 **
MTHFR A1298C
A allele             0.70               0.72
C allele             0.30               0.29
TS 5UTR
2R allele            0.36                NA
3R allele            0.63
TS 3UTR
6bp allele           0.52               0.73
0bp allele           0.46               0.27 **
MDR1 C3435T
C allele             0.38               0.46
T allele             0.62               0.54
MDR1 C1236T
C allele             0.38               0.54
T allele             0.62               0.46
RFC1 G80A
G allele             0.43                NA
A allele             0.57
GGH-401
C allele             0.38                NA
T allele             0.61
MS A2756G
A allele             0.66                NA
G allele             0.34
MTRR A66G
A allele             0.50                NA
G allele             0.50
ATIC C347G
C allele             0.48                NA
G allele             0.52
SHMT1 C1420T
C allele             0.20                NA
T allele             0.80

                 African (14)       Indian (20)
               healthy subjects   healthy subjects
Polymorphism         n=95               n=77

MTHFR C677T
C allele             0.96                NA
T allele             0.04 *
MTHFR A1298C
A allele             0.87                NA
C allele             0.13 **
TS 5UTR
2R allele             NA                 NA
3R allele
TS 3UTR
6bp allele           0.44                NA
0bp allele           0.56
MDR1 C3435T
C allele             0.90               0.35
T allele             0.10 **            0.65
MDR1 C1236T
C allele             0.86               0.28
T allele             0.14 **            0.72 *
RFC1 G80A
G allele              NA                0.72
A allele                                0.28 **
GGH-401
C allele              NA                0.75
T allele                                0.25 **
MS A2756G
A allele              NA                 NA
G allele
MTRR A66G
A allele              NA                 NA
G allele
ATIC C347G
C allele              NA                 NA
G allele
SHMT1 C1420T
C allele              NA                 NA
T allele

P * <0.05 ** <0.001 compared to present study; NA, Data not available

Table II. Genotype distribution of 12 SNPs in folate
metabolism among healthy subjects

Polymorphism          Healthy subjects n=144

                              Expected
                            frequency by
               Observed    Hardy-Weinberg
               frequency        law         P value

MTHFR C677T
CC               0.81           0.80
CT               0.17           0.19
TT               0.02           0.01         0.79
MTHFR A1298C
AA               0.48           0.51
AC               0.46           0.41
CC               0.06           0.08         0.72
TS5UTR *
2R/2R            0.19           0.13
2R/3R            0.34           0.45
3R/3R            0.46           0.40         0.22
TS 3UTR
0bp/0bp          0.23           0.29
6bp/0bp          0.47           0.50         0.25
6bp/6bp          0.31           0.21
MDR1 C3435T
CC               0.14           0.15
CT               0.49           0.47
TT               0.37           0.38         0.95
MDR1 C1236T
CC               0.13           0.15
CT               0.50           0.47
TT               0.37           0.38         0.88
RFC1 G80A
GG               0.27           0.19
GA               0.33           0.49
AA               0.40           0.32         0.07
MSA2756G
AA               0.41           0.43
AG               0.51           0.45
GG               0.08           0.12         0.54
MTRR A66G
AA               0.26           0.25
AG               0.49           0.50
GG               0.25           0.25         0.98
GGH-401
CC               0.14           0.15
CT               0.49           0.47
TT               0.37           0.38         0.95
ATIC C347G
CC               0.23           0.23
CG               0.50           0.50
GG               0.27           0.27         1.00
SHMT1 C1420T
CC               0.02           0.04
CT               0.36           0.32         0.62
TT               0.62           0.64
COPYRIGHT 2011 Indian Council of Medical Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Author:Ghodke, Yogita; Chopra, Arvind; Shintre, Pooja; Puranik, Amrutesh; Joshi, Kalpana; Patwardhan, Bhush
Publication:Indian Journal of Medical Research
Article Type:Report
Geographic Code:9INDI
Date:Mar 1, 2011
Words:2748
Previous Article:Vitamin D deficiency in healthy breastfed term infants at 3 months & their mothers in India: seasonal variation & determinants.
Next Article:Immune status & enzymes activity in blood lymphocytes in adult patients at different stages of acute lymphoblastic leukaemia.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters